Knee Implants Prices Capped; Significant Reduction in Cost   

New Delhi: The Central government has capped the prices of knee implants with effect from August 16, benefitting around 1.5 crore patients in the country suffering from knee ailments and require orthopedic knee implant surgery.

Minister of Chemicals and Fertilizers Ananth Kumar told mediapersons here that now the cost of the most commonly used complete knee implant (Cobalt Chromium ) will come down to Rs 54,720, which was earlier between Rs 1,58,324 to Rs 2.5 lakh.

“This implant is used in more than 80 per cent of the cases,” he said. Other category of implants in which special metals like Titanium and Oxidised Zirconium is used, will come down to Rs 76,600 from Rs 2.5 lakh to Rs 4.5 lakh earlier.

He further said that high flexibility implants and revision implants (that are required after a period of 10 years of initial implant) will come down from Rs 56,490 from Rs 2.75 lakh to Rs 6.5 lakh (high flexibility) and Rs 1,13,950 from Rs 4 lakh to Rs 9 lakh earlier. “However, the GST will be charged on these capped prices,” he added.

Kumar said, “Ensuring the health security of the people of the nation, this is the second step after capping the price of stents required in cardiac surgeries.”

The Minister also said that those who are involved in manufacturing, supplying and trading in knee implants and also the hospitals and institutions involved in treating patients, will be under government’s scanner. “In case anyone is found cheating on the patients by not providing the said implants at capped prices will invite legal action and cancellation of licences can also be done in the regard.”

“Recovery will be made including additional 18 per cent of interest over the amount recovered,” he informed.

According to National Pharmaceutical Pricing Authority (NPPA), around Rs 1,500 crore will be saved by the people in the country on knee procedures every year due to the capping of prices.

The Minister further said that according to World Health Organisation (WHO), by 2020 osteoarthritis will be the fourth largest cause of immobility in the world.

Kumar also said the NPPA has kept into consideration all the aspects of production cost, landing price and margins further deciding upon ceiling prices.

He also urged the industry to cooperate with the government on this move and implement the decision.

The Minister also informed that in reference to the complaints received regarding inflated cardiac stent prices, it had summoned 39 hospitals and is looking into the matter seriously.